Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002329 · ClinicalTrials.gov registry record · Phase 1
A Study of MDL 28,574A in HIV-Infected Patients
A Phase 1 study, sponsored by Hoechst Marion Roussel.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002329: Completed Phase 1 study, sponsored by Hoechst Marion Roussel.
NCT00002329 is a Phase 1 study that has completed, run by Hoechst Marion Roussel. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002329, a Phase 1 study, has completed, sponsored by Hoechst Marion Roussel.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (from which MDL 28574A is derived) following both acute and subchronic dosing.
Interventions
- DRUG Celgosivir hydrochloride
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002329
The ClinicalTrials.gov registry entry for NCT00002329 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoechst Marion Roussel, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Celgosivir hydrochloride is the first listed.
NCT00002329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002329 about?
NCT00002329 is a clinical study titled "A Study of MDL 28,574A in HIV-Infected Patients". To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (f...
What is the current status of trial NCT00002329?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002329?
The interventions under investigation include: Celgosivir hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002329?
This trial is sponsored by Hoechst Marion Roussel, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.